• Molecular NameNelfinavir
  • Synonym1UN; AG1343; Nelfinavir mesylate; NFV; NLF
  • Weight567.795
  • Drugbank_IDDB00220
  • ACS_NO159989-64-7
  • Show 2D model
  • LogP (experiment)5.247
  • LogP (predicted, AB/LogP v2.0)5.16
  • pka9.58; 7.53
  • LogD (pH=7, predicted)5.05
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-5.61
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors4
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds10
  • TPSA127.2
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antiretroviral drug used in the treatment of the human immunodeficiency virus (HIV).
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability50.0
  • Protein binding98.5
  • Volume of distribution (VD)2~7 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmNelfinavir is metabolized by multiple cytochrome CYP isozymes, including CYP3A4.
  • Half life3~5 h
  • ExcretionMetabolites eliminated in faeces
  • Urinary Excretion1~2
  • Clerance12 ml/min/kg
  • ToxicitySide effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
  • LD50 (rat)LD50> 5g/kg
  • LD50 (mouse)N/A